Literature DB >> 8844213

Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers.

N Morral1, T Dörk, R Llevadot, V Dziadek, B Mercier, C Férec, B Costes, E Girodon, J Zielenski, L C Tsui, B Tümmler, X Estivill.   

Abstract

We have analyzed 416 normal and 467 chromosomes carrying 94 different cystic fibrosis (CF) mutations with polymorphic genetic markers J44, IVS6aGATT, IVS8CA, T854, IVS17BTA, IVS17BCA, and TUB20. The number of mutations found with each haplotype is proportional to its frequency among normal chromosomes, suggesting that there is no preferential haplotype in which mutations arise and thus excluding possible selection for specific haplotypes. While many common mutations in the worldwide CF population showed absence of haplotype variation, indicating their recent origins, some mutations were associated with more than one haplotype. The most common CF mutations, delta F508, G542X, and N1303K, showed the highest number of slippage events at microsatellites, suggesting that they are the most ancient CF mutations. Recurrence was probably the case for 9 CF mutations (R117H, H199Y, R347YH, R347P, L558S, 2184insA, 3272-26A-->G, R1162X, and 3849 + 10kbC-->T). This analysis of 94 CF mutations should facilitate mutation screening and provides useful data for studies on population genetics of CF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844213     DOI: 10.1002/(SICI)1098-1004(1996)8:2<149::AID-HUMU7>3.0.CO;2-6

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Can a place of origin of the main cystic fibrosis mutations be identified?

Authors:  Eva Mateu; Francesc Calafell; Maria Dolors Ramos; Teresa Casals; Jaume Bertranpetit
Journal:  Am J Hum Genet       Date:  2001-11-16       Impact factor: 11.025

2.  Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation.

Authors:  Jason W Chien; Lue Ping Zhao; John A Hansen; Wen Hong Fan; Tanyalak Parimon; Joan G Clark
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

3.  Worldwide genetic analysis of the CFTR region.

Authors:  E Mateu; F Calafell; O Lao; B Bonné-Tamir; J R Kidd; A Pakstis; K K Kidd; J Bertranpetit
Journal:  Am J Hum Genet       Date:  2000-12-04       Impact factor: 11.025

4.  Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Authors:  Richard B Moss; Patrick A Flume; J Stuart Elborn; Jon Cooke; Steven M Rowe; Susanna A McColley; Ronald C Rubenstein; Mark Higgins
Journal:  Lancet Respir Med       Date:  2015-06-09       Impact factor: 30.700

5.  Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  Esther van de Vosse; Soegianto Ali; Adriëtte W de Visser; Charles Surjadi; Suwandhi Widjaja; Albert M Vollaard; Jaap T van Dissel
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

6.  Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia.

Authors:  Frauke Stanke; Tim Becker; Vinod Kumar; Silke Hedtfeld; Christian Becker; Harry Cuppens; Stephanie Tamm; Jennifer Yarden; Ulrike Laabs; Benny Siebert; Luis Fernandez; Milan Macek; Dragica Radojkovic; Manfred Ballmann; Joachim Greipel; Jean-Jacques Cassiman; Thomas F Wienker; Burkhard Tümmler
Journal:  J Med Genet       Date:  2010-09-12       Impact factor: 6.318

7.  N1303K (c.3909C>G) mutation and splicing: implication of its c.[744-33GATT(6); 869+11C>T] complex allele in CFTR exon 7 aberrant splicing.

Authors:  Raëd Farhat; Géraldine Puissesseau; Ayman El-Seedy; Marie-Claude Pasquet; Catherine Adolphe; Sandra Corbani; André Megarbané; Alain Kitzis; Véronique Ladeveze
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.